Page 21 - Boxed Warning News Today

Hepzato Kit™ (melphalan/Hepatic Delivery System) is approved as a liver-directed treatment for adults with metastatic uveal melanoma with unresectable hepatic metastases.

The FDA granted accelerated approval to Pfizer Inc's (NYSE: PFE) Elrexfio (elranatamab-bcmm) for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at 

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a...

The FDA has granted accelerated approval to Elrexfio™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma.

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical... -Today at 08:04 am- MarketScreener

The approval of ELREXFIO is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study ELREXFIO is the first off-the-shelf fixed-dose subcutaneous... -Today at 02:09 pm- MarketScreener

Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raiseFavorable outcome at Markman hearing in pending CINVANTI® ANDA patent... -Today at 04:06 pm- MarketScreener

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

The FDA has approved Talvey (talquetamab-tgvs), a bispecific therapy, for heavily pretreated multiple myeloma.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued an...